Russia hurts Dr Reddy's in Q1 but US NDAs progress
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratories reported a 7% increase in revenues to INR37.6bn ($591m) for the first quarter ended June, but growth was impacted by a significant drop in sales in emerging markets and flat numbers in the pharmaceutical services and active ingredients (PSAI) business. Net profits increased by 14% to INR6.3bn.